



## REGENXBIO to Present at Upcoming Investor Conferences

May 06, 2021 04:05 PM EDT

ROCKVILLE, Md., May 6, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will present at the following May investor conferences, which will each be held in a virtual meeting format:

**Bank of America Securities 2021 Virtual Health Care Conference Day**

**Fireside Chat:** Wednesday, May 12, 2021 at 12:30 p.m. E.T.

**RBC Capital Markets 2021 Global Healthcare Virtual Conference**

**Fireside Chat:** Tuesday, May 18, 2021 at 10:55 a.m. E.T.

**UBS Global Healthcare Virtual Conference**

**Fireside Chat:** Tuesday, May 25, 2021 at 11:00 a.m. E.T.

A live webcast of each fireside chat can be accessed in the 'Investors' section of REGENXBIO's website at [www.regenxbio.com](http://www.regenxbio.com). An archived replay of each webcast will be available on the same website for approximately 30 days following each fireside chat.

**About REGENXBIO Inc.**

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV<sup>®</sup> Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

**Contacts:**

Tricia Truehart  
Investor Relations and Corporate Communications  
347-926-7709  
[ttruehart@regenxbio.com](mailto:ttruehart@regenxbio.com)

Investors:  
Brendan Burns, 212-600-1902  
[brendan@argotpartners.com](mailto:brendan@argotpartners.com)

Media:  
David Rosen, 212-600-1902  
[david.rosen@argotpartners.com](mailto:david.rosen@argotpartners.com)



 View original content to download multimedia: <http://www.prnewswire.com/news-releases/regenxbio-to-present-at-upcoming-investor-conferences-301285276.html>

SOURCE REGENXBIO Inc.